Avadel Pharmaceuticals
Dublin
About Avadel Pharmaceuticals
Avadel Pharmaceuticals is a biopharmaceutical company dedicated to developing modified medications that address patient challenges with existing treatment options. The company's primary focus is on narcolepsy, for which its commercial product is LUMRYZ (sodium oxybate for extended-release oral suspension). LUMRYZ is notable for its once-at-bedtime dosing regimen for treating cataplexy or excessive daytime sleepiness in patients with narcolepsy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $190.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Mar 2023)
- Ticker: nasdaq:AVDL
- Website: avadel.com
- Phone: (636) 449-1830
Industries & Categories
Biotechnology, Information Technology, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/avadel-pharmaceuticals-28068 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.